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Case report
 Our patient (18 years old) first noticed symptoms of  re-
duced visual acuity two years before seeking medical advice 
(from an ophthalmologist) when he could not read the 
number plate of  the car during his driving test. He also 
reported tiredness, lethargy, lack of  concentration, slow 
mentation, and memory problems for the previous 2 years. 
He shaved once a week. He reported normal erectile func-
tion. The family history was positive for hypothyroidism in 
his mother.
He looked much younger than his age. He had male pat-
tern body hair distribution; however, hair was sparse. His 
corrected visual acuities were 6/12 right and 6/24 left, and 
ocular examination was normal. His electrophysiology 
showed subtle delay in the pattern of  visual evoked poten-
tials on the right, with borderline responses on the left. Vis-
ual field testing with the Octopus perimeter showed subtle 
superotemporal defects bilaterally.  
Investigations
Blood tests showed primary hypothyroidism with mark-
edly high TSH, hypogonadotrophic hypogonadism, low 
IGF-1, and hyperprolactinemia (Table). Random cortisol 
was low, but the stimulated cortisol rose to 738 nmol/l 
(normal value >550 nmol/l).
A CT scan of  the head showed a mass in the sella tur-
cica. An MRI scan confirmed a pituitary mass extending 
upward into the suprasellar cistern, elevating and com-
pressing the optic chiasm (Figs. 1-5).
Treatment
Thyroxine replacement was started with monitoring of  
the patient's clinical condition and biochemical profile. 
Surgical treatment was to be considered only if  there was 
deterioration in his visual fields. Frequent clinic visits were 
organized to properly monitor the treatment.
Outcome and followup 
The patient made a tremendous improvement sympto-
matically and biochemically over a period of  3 months, 
with thyroid hormone replacement initially at a dose of  25 
mcg, increased rapidly to 75 mcg. All of  the pituitary hor-
mone levels returned to the reference range, including tes-
tosterone and cortisol. MRI 3 months later (Fig. 6) showed 
a reduction in the size of  the mass in the pituitary fossa 
such that it no longer displaced the optic nerves or chiasm. 
The possibility of  a primary pituitary mass could not be 
excluded; however, there was a definite reduction in the 
size of  the gland, which was no longer displacing the optic 
nerve or chiasm.
Clinical improvement continued during subsequent clinic 
visits. The patient's scan in ten months (Fig. 7) showed fur-
ther reduction in the size of  the pituitary gland, with persis-
tent changes. He remains on thyroxine, and to date (12 
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Fig. 2 (right). MRI scan 
on presentation. Post-
contrast, fat-saturated,  
T1-weighted coronal 
view.
Table 1. Laboratory investigations
Dates At presentation 3 weeks later 11 weeks later 10 months later
Random Cortisol nmol/l 
(171-536) 
269 186 189
Free T4 pmol/l (12.0-22.0) 0.7 3.9 10.8 15.5
Free T3 pmol/l (4.0-6.8) <0.4
TSH mIU/l(0.27-4.20) >100 >100.00 3.83 1.53
LH IU/l (1.7-8.6) 2.0 2.3 3.2
FSH IU/l (1.5-12.4) 5.7 5.5 1.7
Prolactin mIU/l (86-324) 1134 1326 451
Testosterone nmol/l, 
(7.6-31.4)
7.1 7.0 18.9
Growth hormone needs 
units
0.4
IgF-1 nmol/l (16.5-55.1), 10.3 11.2 30.4
Glucose units 4.7
Levothyroxine dose Started 25 
mcg/day
Increased to 75 
mcg/day
On 75 mcg/day 75 mcg/day
Insulin tolerance test 
showed adequate cortisol 
reserves, which rose to 
738nmol/l (normal re-
sponse value >550 nmol/l). 
Fig. 1 (left). MRI scan 
image on presenta-
tion. Noncontrast, fat-
saturated, T1-
weighted sagittal view.
months since initiation of  therapy), he has had no clinical 
symptoms or signs.
While pituitary hyperplasia is an uncommon diagnosis, 
the endocrinologist or neuroradiologist should consider it a 
possibility in the appropriate clinical scenario. A multidisci-
plinary approach helps in making these decisions and in 
providing appropriate treatment.
With the improvement in imaging techniques, we are 
increasingly coming across scenarios of  abnormal findings 
on the imaging before the biochemical investigations. This 
case emphasizes the importance of  complete biochemical 
investigations before interpreting imaging findings for en-
docrine diagnosis.
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Fig. 3. MRI scan image on presentation. Postcontrast, fat-
saturated, T1-weighted sagittal view showing homogeneous 
contrast uptake.
Fig. 4. MRI scan on presentation. Postcontrast, fat-
saturated, T1-weighted coronal view showing nipple sign in 
the enlarged pituitary gland (arrow).
Fig. 5. MRI scan at presentation. T2 coronal section show-
ing suprasellar extension and compression on optic chiasm.
Fig. 6. MRI after three months. Noncontrast T2 coronal 
image. Note reduction in size of pituitary gland. Nipple sign 
is also reversing.
Discussion
Primary hypothyroidism can lead to hypertrophy of  thy-
rotroph cells in the adenohypophysis, resulting in enlarge-
ment of  the anterior pituitary (1). It results from the loss of  
thyroxine feedback inhibition (2) and the subsequent over-
production of  thyrotropin-releasing hormone (TRH) (3). 
Pituitary hyperplasia due to primary hypothyroidism occurs  
most frequently among all feedback tumors, reported as 
33.3% (4). Despite continuing improvements in imaging 
techniques, it is not always possible to distinguish between 
pituitary adenomas and pituitary hyperplasia on CT or 
MRI scans. In this patient, TSH-producing adenoma and 
hyperplasia of  anterior pituitary thyrotroph would be the 
most likely possibilities in view of  the very high levels of  
TSH. The therapeutic option for primary hypothyroidism 
(thyroxine replacement)  completely differs from that for 
TSHoma (usually, surgery).
Pituitary hyperplasia due to primary hypothyroidism is 
defined by an enlargement of  the pituitary follicle, hyper-
plasia of  hormone-producing cells, and changes of  pitui-
tary structure. The differences in ultrastructure between 
hyperplastic cells and normal pituitary cells are very obvi-
ous. Hyperplasia is always caused by pathological factors, 
and this is mostly found in primary hypothyroidism (5). The 
incidence of  pituitary hyperplasia in patients with hypothy-
roidism varies from 25% to 81% (6); a high incidence (70%) 
is reported in patients with TSH levels ≥50 μIU/ml (7). 
Because TRH (thyrotropin-releasing hormone) also has a 
weak stimulatory effect on lactotroph cells, mild to moder-
ate hyperprolactinemia may occur in about three-quarters 
of  patients (6). Children and young patients with pituitary 
hyperplasia and primary hypothyroidism do not usually 
present with symptoms secondary to sellar expansion (3%) 
but rather with symptoms of  hypothyroidism (6). These 
children present with reduced or arrested growth due to 
primary hypothyroidism, and growth hormone (GH) pro-
duction may be decreased because thyroxine is one of  the 
factors stimulating GH synthesis (8). Longstanding primary 
hypothyroidism may also lead to permanent pituitary dam-
age, with insufficiency in one or more pituitary hormones 
(9). Thyroxine replacement therapy led to a reduction in 
the size of  the gland in 85% of  patients with pituitary hy-
perplasia (7). Surgery should be reserved for decompression 
of  the optic chiasm or to obtain a pathological diagnosis in 
the case of  a pituitary mass that does not respond to, or 
worsens under, thyroid hormone replacement (9). 
MRI alone has proven unable to reliably differentiate 
between tumor and hyperplasia; however, a midline 
prominence of  a pituitary mass with smooth contours (the 
“nipple sign”) has been proposed as suggestive of  pituitary 
hyperplasia (10). This appearance has also been noticed in 
pituitary adenomas. Indeed, the most frequent radiologic 
finding in primary hypothyroidism, both by CT and MRI, 
is a pituitary mass with supra-sellar extension (11). 
The enhancing pattern of  pituitary masses on postcon-
trast scans could allow them to be differentiated from each 
other. Pituitary adenomas may be homogeneous or hetero-
geneous. Typically, they have a slightly lower signal than a 
normal gland on unenhanced, T1-weighted images. Con-
trast medium allows better visualisation of  this difference. 
Hyperplastic glands show a homogeneous pattern on un-
enhanced T1- and T2-weighted images and enhance uni-
formly on postcontrast T1-weighted images, as hyperplasia 
affects the gland uniformly (12).
The MRI scan in this case shows diffuse enhancement of 
the pituitary gland on T1, postcontrast, fat-rich images. 
Pituitary macroadenomas (adenomas more than 1 cm in 
size) on the T1 sequence are mostly isointense to gray mat-
ter (13); however, larger lesions are often heterogeneous 
and vary in signal due to areas of  cystic change/necrosis/
hemorrhage. On a T1 sequence with gadolinium, the solid 
components often demonstrate moderate to bright en-
hancement. Normal pituitary tissues can be identified in 
some cases as a thin outer rim at the margin of  macro-
adenomas. 
Microadenomas (adenomas less than 1 cm in size) are 
usually isointense to a normal pituitary gland on a T1 se-
quence. Postcontrast T1 sequences demonstrate a rounded 
region of  delayed enhancement compared to the rest of  
the gland (14). The delayed images are variable, ranging 
from hypo-enhancement (most common), to isointense to 
the rest of  the gland, to hyperintense (retained contrast). 
The pituitary microadenomas are best visualized on 
earlier-phase, contrast-enhanced dynamic MR images, 
with a signal intensity lower than that seen on images of  
the normal pituitary gland (15).
Lymphocytic hypophysitis can also present as a pituitary 
mass that (on T1 sequence) is isointense with slight signal 
heterogeneity in the affected area, and the normal poste-
rior pituitary bright spot may be absent (13). The affected 
area can variably enhance, usually homogeneously (16), 
and dural enhancement may be present (13) on the post-
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Fig. 7. MRI after ten months. Noncontrast T2 coronal im-
age. Pituitary gland is smaller, with minimal residual 
changes.
contrast, T1, fat-rich sequence. In addition, the infundibu-
lum may be thickened (13). On a T2 sequence, hypointen-
sity in parasellar region can be present and may be useful in 
differentiating the the mass from a pituitary adenoma (17).
Pituitary venous congestion could also present as a pitui-
tary mass, which could have a sequential enhancement 
pattern. In 1983, Bonneville et al (18) described the pitui-
tary tuff  sign, which is the initial enhancement of  the sec-
ondary portal circulation at the insertion site of  the infun-
dibulum, with progressive centrifugal enhancement of  the 
anterior pituitary lobe. Sakamoto et al (15) used sagittal and 
coronal planes for dynamic MR imaging of  the normal 
pituitary gland. They found that, on the sagittal sections, 
the signal intensity increased first in the posterior lobe of  
the pituitary gland; this was followed by enhancement of  
the anterior lobe adjacent to the junction with the infun-
dibulum. On the coronal sections of  the anterior lobe, the 
anterior pituitary lobe at the junction with the infundibu-
lum showed earliest enhancement, the middle portion 
showed slightly delayed enhancement, and the lateral por-
tion of  the anterior lobe enhanced last. They also noted 
that the washout of  contrast medium from the posterior 
lobe was slightly faster than that from the anterior lobe. 
Patients treated with thyroxine need MRI monitoring of  
their pituitary glands to confirm reduction in the size of  the 
mass and subsequent complete resolution. The diagnosis 
needs to be revisited if  the mass does not reduce in size 
following treatment with thyroxine. Our patient did show 
the nipple sign on his initial and subsequent MRI pituitary 
scans. 
The clinical evolution of  the response of  pituitary hyper-
plasia to thyroxine should be monitored closely, because of  
the rare possibility of  acute neurological manifestations, 
such as the development of  pseudotumor cerebri and 
“paradoxical” thyroid-hormone-therapy-induced visual 
failure, or the possibility of  an incidental nonthyrotropic 
pituitary tumor that does not regress on thyroxine therapy 
(19). In the case of  marked regression of  pituitary enlarge-
ment, without complete normalization in pituitary mor-
phology, the clinical significance of  a persistent minimal 
abnormality detectable by either CT or MRI remains 
unclear.
Our patient noticed improvement of  his visual symptoms 
soon after the initiation of  thyroxine therapy. His MRI 3 
months after thyroxine therapy showed significant im-
provement, and a subsequent scan in 10 months showed 
further reduction in pituitary gland size. The residual 
changes are most likely the effects of  longstanding hypothy-
roidism that in our patient may take longer to resolve com-
pletely or may persist indefinitely.  
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